Hot Biotech Stocks News: Add these 40 to your Watch List
The vast majority of biotech stocks failed to join a broad market rally on Wednesday with Pacific Biosciences of California (NASDAQ
ACB) facing the biggest fall of 13.91%.
Amyris Inc (NASDAQ:AMRS) extended 5-day losing streak after a news that the company has added $37.25 million in cash and $5 million in debt cancellation from a $42.25 million private placement led by Total and Biolding Investment.
Incyte Corporation (NASDAQ:INCY) lost 4.17% after Morgan Stanley downgraded the stock from an “equal weight” rating to an “underweight” rating.
Cell Therapeutics Inc (NASDAQ:CTIC) and Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) both fell more than 4% while Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX), Neostem Inc. (NYSEAMEX:NBS) and Dendreon Corporation (NASDAQ
NDN) dropped in a range of 3 to 4 percent.
Curis, Inc. (NASDAQ:CRIS) suffered fifth decline in row.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) retreated 2.60% after announcing common stock offering.
VIVUS, Inc. (NASDAQ:VVUS) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) were under notable pressure after Arena Pharmaceuticals (NASDAQ:ARNA) said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) provided a Day 180 list of outstanding issues.
Celsion Corporation (NASDAQ:CLSN) failed to sustain rally seen after the company expanded a drug development deal with a Chinese drug maker.
Despite hitting new high yesterday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) ended below the trend line.
Celgene Corporation (NASDAQ:CELG) was down before its earnings report on Thursday morning.
Biogen Idec Inc. (NASDAQ:BIIB) declined after a Forbes report that Wall Street is expecting lower third quarter profit for the company.
Amgen, Inc. (NASDAQ:AMGN) declined on lower Q4 earnings.
More on the down side, Sequenom, Inc. (NASDAQ:SQNM), Peregrine Pharmaceuticals (NASDAQ PHM), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Viropharma Inc (NASDAQ:VPHM), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Gilead Sciences, Inc. (NASDAQ:GILD) each was down at-least 1%.
On the other hand, Exelixis, Inc. (NASDAQ:EXEL), Illumina, Inc. (NASDAQ:ILMN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) each fell as much as 1% by the end of trade on Wednesday.
Turning to upside, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) led all upbeat biotech stocks after its rival Celgene (CELG) declared Abraxane Phase III update on Tuesday night.
PharmAthene, Inc. (NYSEAMEX IP) jumped 11.54% a day after its presentation at the Noble Financial Capital Markets Ninth Annual Equity Conference.
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) advanced 4.60% after providing preliminary (unaudited) forecast of net product revenue from sales of OFIRMEV® (acetaminophen) injection for the three-months ended December 31, 2012, of about $17.1 million.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rose after the company declared election of Stephen R. Biggar to its Board of Directors.
Santarus, Inc. (NASDAQ:SNTS) gained on publication of upbeat data from a double-blind, placebo-controlled, multi-center pivotal study with CYCLOSET (bromocriptine mesylate) tablets.
More on the upside, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Corcept Therapeutics Incorporated (NASDAQ:CORT), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), DARA Biosciences Inc (NASDAQ ARA), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) all ended in green.
